Abstract
The applications of chemotherapy for the treatment of AML have been unchanged over the past three decades, with only 30% of patients demonstrating disease-free survival (DFS) [118]. Despite achieving CR following induction chemotherapy, the majority of patients relapse and succumb to their disease [6]. In view of the limitations encountered by cytarabine/anthracycline based regimes, attention has shifted to immunotherapy as a means to treat AML and provide significant long-term DFS. This chapter will discuss the role of the immune system and recent advances in immunotherapy for the treatment of AML, focusing on cellular and non-cellular approaches.
MeSH terms
-
Aminoglycosides / therapeutic use
-
Animals
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Cancer Vaccines / therapeutic use
-
Clinical Trials as Topic
-
Cytokines / therapeutic use
-
Gemtuzumab
-
Graft vs Host Disease / etiology
-
Graft vs Host Disease / prevention & control
-
Graft vs Leukemia Effect
-
Hematopoietic Stem Cell Transplantation / adverse effects
-
Humans
-
Immunotherapy*
-
Immunotherapy, Active
-
Immunotherapy, Adoptive
-
Killer Cells, Natural / transplantation
-
Leukemia, Myeloid, Acute / drug therapy
-
Leukemia, Myeloid, Acute / immunology
-
Leukemia, Myeloid, Acute / surgery
-
Leukemia, Myeloid, Acute / therapy*
-
Lymphocyte Transfusion / adverse effects
-
Mice
-
Neoplasm Proteins / antagonists & inhibitors
-
Neoplasm Proteins / immunology
-
T-Lymphocytes, Cytotoxic / transplantation
-
Transplantation, Homologous
Substances
-
Aminoglycosides
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Cancer Vaccines
-
Cytokines
-
Neoplasm Proteins
-
Gemtuzumab